Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/129142USE OF GLP-2 ANALOGUES IN PATIENTS WITH RENAL INSUFFICIENCY
WO 23.06.2022
Int.Class A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
Appl.No PCT/EP2021/085846 Applicant ZEALAND PHARMA A/S Inventor SONNE, Kim
The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.
2.WO/2022/132202COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO 23.06.2022
Int.Class C07K 14/495
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
495Transforming growth factor (TGF)
Appl.No PCT/US2021/010067 Applicant BICARA THERAPEUTICS INC. Inventor MARIGOWDA, Shivakumar, Bhadravathi
Provided herein are methods of treating cancer by administering to a subject having cancer an antibody, or functional fragment or functional variant thereof, that specifically binds programmed cell death protein 1 (PD1); and a fusion protein that comprises a targeting moiety and an immunomodulatory moiety, wherein: i) said targeting moiety specifically binds epidermal growth factor receptor (EGFR); and (ii) said immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of transforming growth factor-beta receptor Il (TGFβRII).
3.WO/2022/132712METHODS OF TREATING DIABETES
WO 23.06.2022
Int.Class A61K 38/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
28Insulins
Appl.No PCT/US2021/063235 Applicant ELI LILLY AND COMPANY Inventor CARR, Molly Corbett
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
4.WO/2022/132756BIALLELIC KNOCKOUT OF TRAC
WO 23.06.2022
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Appl.No PCT/US2021/063290 Applicant EMENDOBIO INC. Inventor IZHAR, Lior
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-1932 and compositions, methods, and uses thereof.
5.WO/2022/133326BI-FUNCTIONAL LINEAR FUSION COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF
WO 23.06.2022
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/US2021/064224 Applicant CULLINAN AMBER CORP. Inventor MEHTA, Naveen
Disclosed herein are immunomodulatory fusion proteins comprising an IL-2; an IL-12, a collagen-binding domain, and a linear polypeptide spacer, methods of making and using the same. The immunomodulatory fusion proteins disclosed herein are useful for the treatment of cancer.
6.WO/2022/133461DELIVERY OF ABETA VARIANTS FOR AGGREGATION INHIBITION
WO 23.06.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2021/072944 Applicant BAYLOR COLLEGE OF MEDICINE Inventor PARK, Kyung-Won
Aspects of the present disclosure are directed to compositions and methods for treating a subject having a neurodegenerative disorder, disease, or condition. Certain aspects relate to treatment with a therapeutically effective amount of a composition comprising a vector encoding an Aβ peptide variant. Further aspects relate to methods of inhibiting aggregation of endogenous Aβ peptide in vivo by contacting at least one such peptide with a therapeutically effective amount of an expressed Aβ peptide variant from a vector encoding the Aβ peptide variant, said vector in a composition.
7.WO/2022/131322NEURON ACTIVATOR
WO 23.06.2022
Int.Class A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
Appl.No PCT/JP2021/046462 Applicant KYOTO UNIVERSITY Inventor TAKAHASHI Jun
A purpose of the present invention is to develop and provide a neuron activator for activating brain neurons. Another purpose of the present invention is to provide an agent for accelerating, when cell transplantation is performed for a neurological disorder, at least one of engrafting of cells being transplanted, differentiation of said engrafted cells into neurons, and maturation of said neurons. The present invention provides: a neuron activator including a protein selected from the group consisting of Lysozyme (LYZ), Secreted Phosphoprotein 1 (SPP1), Progranulin (PGrn), Cathepsin D (Ctsd), Cathepsin S (Ctss), Apolipoprotein D (Apod), Sparc, CD52, Macrophage-Expressed Gene 1 (MPEG1), C-C Motif Chemokine Ligand 2(CCL2), Cystatin F(CST7), Rac Family Small GTPase 2 (RAC2), Serpin Family A Member 3(SERPINA3), Anosmin 1 (ANOS1), Kallikrein Related Peptidase 6 (KLK6), α2-Macroglobulin (A2M), GM14295, Galectin 3 Binding Protein (LGALS3BP), Apolipoprotein C1 (APOC1), and orthologs thereof, or an active fragment thereof, or a nucleic acid encoding same; and a cell transplantation adjuvant containing said agent.
8.WO/2022/131922CATH2 DERIVATIVES FOR STIMULATING INNATE IMMUNE MEMORY
WO 23.06.2022
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No PCT/NL2021/050776 Applicant UNIVERSITEIT UTRECHT HOLDING B.V. Inventor HAAGSMAN, Hendrik Peter
The invention relates to methods for activating, inducing or promoting innate immune memory in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof. The invention further relates to methods of improving antimicrobial treatment in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof and to a use of CATH2 or a derivative thereof as an adjuvant for a pathogen-specific vaccine.
9.WO/2022/129312PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS
WO 23.06.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/EP2021/086148 Applicant ZEALAND PHARMA A/S Inventor VILLADSEN, Jesper Skodborg
The present invention relates to pharmaceutical compositions comprising particular preservatives.
10.WO/2022/130016TUMOR INFILTRATING LYMPHOCYTES AND ANTI-CD47 THERAPEUTICS
WO 23.06.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/IB2021/000882 Applicant INSTIL BIO (UK) LIMITED Inventor GUEST, Ryan
The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.